Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: Focus on panitumumab

George P. Kim, Axel Grothey

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations


The human anti-epidermal growth factor receptor (EGFR) monoclonal antibody, panitumumab, represents a significant advance in the treatment of colorectal cancer. The strategy to target this receptor is based on sound cancer biology demonstrating its essential role in colorectal carcinogenesis. Panitumumab, unlike its predecessor, cetuximab, is fully human and thus reduces the incidence of hypersensitivity reactions. But, in several clinical trials, unexpected toxicities have become more apparent, raising concerns of how readily panitumumab can ucceed cetuximab. This paper reviews the development of this agent and the pivotal clinical trials that help our understanding of its optimal use in colorectal cancer treatment. 7COPY; 2008 Dove Medical Press Limited. All rights reserved.

Original languageEnglish (US)
Pages (from-to)223-228
Number of pages6
JournalBiologics: Targets and Therapy
Issue number2
StatePublished - 2008


  • Bevacizumab
  • Cetuximab
  • Chemotherapy
  • Colorectal cancer
  • Irinotecan
  • Oxaliplatin
  • Panitumumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Oncology
  • Gastroenterology
  • Pharmacology (medical)


Dive into the research topics of 'Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: Focus on panitumumab'. Together they form a unique fingerprint.

Cite this